NEXENTIS TECHNOLOGIES INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $39.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-31
- NEXENTIS TECHNOLOGIES INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $39.00K.
- NEXENTIS TECHNOLOGIES INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $16.00K, a 66.16% decline from fiscal 2022.
- NEXENTIS TECHNOLOGIES INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $47.28K, a 76.53% decline from fiscal 2021.
- NEXENTIS TECHNOLOGIES INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $201.47K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|
| 2025-12-31 | $39.00K 10-K · filed 2026-03-31 | |
| 2023-12-31 | $16.00K 10-K · filed 2025-03-31 | $15.71K 10-K · filed 2024-04-01 |
| 2022-12-31 | $47.28K 10-K · filed 2024-04-01 | |
| 2021-12-31 | $201.47K 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |